Innovation & Entrepreneurship in Drug Discovery & Development
Monday, September 10 2012
8:00 am – 6:00 pm
Location: Joseph P Martin Conference Center, Harvard Medical School
Emerging Business Trends in Biomedicine
Co-Sponsored by HBS Healthcare Alumni & Pfizer
- Jose-Carlos Gutierrez-Ramos, PhD, SVP R&D, Biotherapeutics, Pfizer
- Wolfgang Klietmann, MD, Lecturer on Pathology, Harvard Medical School
In the recent past pharmaceutical companies have been forging new relationships with academic institutions with the goals of spurring innovation in drug development and reversing pipeline attrition. Academic research labs posssess a repository of experience not existing in the pharmaceutical industry laboratories. However, bringing a new compound to market (which can take over a decade and cost + $1 billion) needs the collaboration of both academia and industry: specifically the R&D resources, manufacturing experience, and financing power of big pharma.
The symposium will explore the complexities of this process from scientific discovery through commercialization as well as provide a forum for a dialogue regarding the challenges of the entire industry. In specific we will explore how Pfizer's unique CTI (Centers of Therapeutic Innovation) model creates an amalgamated new collaboration between scientists from academia and industry that will assist all collaborators to better understand the disruptive changes in the drug-developing industry, and how to work together productively for the future.
Date: Monday, September 10, 2012
Time: 8:00am - 6:00pm
Venue: Joseph P. Martin Conference Center, Harvard Medical School